Q3 2024 13F Holders as of 9/30/2024
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
60.3M
-
Number of holders
-
159
-
Total 13F shares, excl. options
-
45.6M
-
Shares change
-
+819K
-
Total reported value, excl. options
-
$2.07B
-
Value change
-
+$42.3M
-
Put/Call ratio
-
7.66
-
Number of buys
-
84
-
Number of sells
-
-76
-
Price
-
$45.43
Significant Holders of Janux Therapeutics, Inc. - Common Stock (JANX) as of Q3 2024
197 filings reported holding JANX - Janux Therapeutics, Inc. - Common Stock as of Q3 2024.
Janux Therapeutics, Inc. - Common Stock (JANX) has 159 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 45.6M shares
of 60.3M outstanding shares and own 75.6% of the company stock.
Largest 10 shareholders include RA CAPITAL MANAGEMENT, L.P. (9.17M shares), FMR LLC (7.82M shares), JANUS HENDERSON GROUP PLC (2.52M shares), BlackRock, Inc. (2.42M shares), Paradigm Biocapital Advisors LP (2.4M shares), ADAGE CAPITAL PARTNERS GP, L.L.C. (2.08M shares), VANGUARD GROUP INC (1.85M shares), Woodline Partners LP (1.6M shares), EcoR1 Capital, LLC (1.47M shares), and STATE STREET CORP (1.36M shares).
This table shows the top 159 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.